SLC5A2 and hydrops fetalis: Compared with placebo, SGLT-2 inhibitor therapy was associated with 10% reduced risk for major adverse cardiovascular events (pooled HR: 0.90; 95% CI: 0.85–0.95), 22% reduced risk for the composite outcome of cardiovascular death or HF hospitalization (pooled HR: 0.78; 95% CI: 0.73–0.84), and 38% reduced risk for kidney failure outcomes (pooled HR: 0.62; 95% CI: 0.56–0.70) [21].